Kendle Internat (KNDL)

Kendle Internat (KNDL) Stock Quote Information

Kendle International Inc., a clinical research organization, provides Phase I-IV clinical development services on a contract basis to the biopharmaceutical industry worldwide. The company operates through two segments: Early Stage and Late Stage. The Early Stage segment focuses on the high-end scientific exploratory medicine area, from first-in-human studies to proof-of-concept stages. This segment also supports Phase I studies in established compounds, including bioequivalence and pharmacokinetics studies. The Late Stage segment conducts Phase II to IV clinical trials, as well as provides a range of services, including clinical monitoring, investigator recruitment, patient recruitment, data management, and study reports to assist customers with their drug development process. This segment also oversees various steps of a study, from award to close out of a study; designs and conducts Phase IIIB and IV studies; focuses on health economics and outcomes research, observational studies, scientific events, and medical education services; and provides services to the federal government and health care foundation oriented organizations. In addition, it offers regulatory and consulting services at every stage of drug and device development, as well as designs clinical programs and clinical trial protocols, reviews programs, and provides gap analysis to assist sponsors in achieving their clinical development strategies; offers consulting services for nonclinical development for small molecules, biologicals, vaccines, and devices; assists with the U.S. Food and Drug Administration application process; and assists customers with the collection, analysis, and reporting of drug safety data. Further, this segment offers statistical support for Phase I to IV clinical trials and submissions. Kendle International Inc. operates in North America, Europe, Asia/Pacific, Latin America, and Africa. The company was founded in 1981 and is based in Cincinnati, Ohio.